At the Alzheimer's Association International Conference, scientists from the FDA presented an exploratory analysis of risk ...
The approval is based on clinical trial data on intravenous Leqembi and data suggesting subcutaneous formulation leads to similar results.
The firm said the AZUR-1 trial, evaluating Jemperli in patients with dMMR and MSI-high tumors met its primary endpoint.
In the cooperative research and development agreement, the partners will use Apertura's TfR1 CapX capsid to deliver a gene therapy to the central nervous system.
The Phase I/II trial will enroll pediatric patients with the seizure-causing condition who will be dosed every six months.
The biotech is tackling common cardiovascular conditions by targeting risk factors like high cholesterol, triglycerides, and ...
An analysis from the FLEX study showed that only patients in MammaPrint's highest risk category benefitted from the addition ...
Geopolitical tensions with the US and the allure of cheaper and quicker trials are drawing Chinese biotechs developing ...
NEW YORK – Confluence Genetics on Thursday said it is advancing treatments for hepatocellular carcinoma using its newly launched CRISPR platform, called Cas-CLEAR, and seeking codevelopment partners.
The company is trying again after receiving a complete response letter from the FDA last year requested more data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results